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ABSTRACT
Defects of the translation apparatus in human
mitochondria are known to cause disease, yet
details of how protein synthesis is regulated in this
organelle remain to be unveiled. Here, we character-
ize a novel human protein, C7orf30 that contributes
critically tomitochondrialtranslation andspecifically
associates with the large subunit of the mitochon-
drial ribosome (mt-LSU). Inactivation of C7orf30 in
human cells by RNA interference results in respira-
tory incompetence owing to reduced mitochondrial
translation rates without any appreciable effects on
the steady-state levels of mitochondrial mRNAs and
rRNAs. Ineffective translation in C7orf30-depleted
cells or cells overexpressing a dominant-negative
mutant of the protein results from aberrant
assembly of mt-LSU and consequently reduced for-
mation of the monosome. These findings lead us to
propose that C7orf30 is a human assembly and/or
stability factor involved in the biogenesis of the
large subunit of the mitochondrial ribosome.
INTRODUCTION
It is estimated that 3–5% of all human proteins are
localized to mitochondria (1), vital organelles that
supply energy to the cell through the process of oxidative
phosphorylation (OXPHOS). Approximately 90 proteins
form the ﬁve enzyme complexes that perform OXPHOS
and 13 of those are encoded in the mitochondrial genome
(mtDNA). For this reason, mitochondria contain a
separate translation apparatus, necessary for the synthesis
of the mtDNA-encoded polypeptides of the OXPHOS
system. The RNA components (2 rRNAs and 22
tRNAs) of the mitochondrial translation machinery are
encoded by mtDNA, while all protein components
including the mitochondrial ribosomal subunits, transla-
tion factors, tRNA synthetases, tRNA-modifying
enzymes, and other auxiliary factors are encoded by
nuclear genes and imported to mitochondria from the
cytosol. Human mitoribosomes consist of a large
(mt-LSU) and small subunit (mt-SSU) of 39S and 28S,
respectively, and the entire ribosome has a sedimentation
coefﬁcient of 55S (2).
Many genetic defects can lead to perturbations of the
OXPHOS system and result in multi-system, often fatal,
human diseases. These genetic defects can be located
within nuclear DNA (nDNA) or mtDNA. Isolated
OXPHOS deﬁciencies, that affect a speciﬁc biochemical
activity of the OXPHOS system, are usually caused by
mutations in structural genes (coding for a speciﬁc com-
ponent of the OXPHOS machinery) or in genes encoding
proteins responsible for the assembly of a particular re-
spiratory complex. In contrast, inherited pathological
mutations, affecting either mitochondrially or nuclearly
encoded components of the mitochondrial translation
machinery, are associated with combined OXPHOS
deﬁciencies affecting multiple enzymes involved in
cellular respiration. Many mutations in mtDNA-encoded
genes for the RNA components of the mitochondrial
translation apparatus (mt-rRNAs and mt-tRNAs) have
been identiﬁed, and detection of yet uncharacterized
mutations is relatively straightforward. On the contrary,
a group of mutations in nuclear gene products involved in
mitochondrial translation linked to human disease has
emerged only in recent years (3). This group currently
contains <20 genes including those that encode: transla-
tion elongation factors, proteins of the mitoribosomal
subunits, several tRNA synthetases, tRNA-modifying
enzymes [for recent review see (4)] and also other transla-
tion auxiliary proteins, such as TACO1 (CCDC44) (5) or
c12orf65 (6). Given the complexity of the mitochondrial
translation system, this list is unlikely to be complete.
By analogy to other translation systems one would, for
example, anticipate that mitoribosome assembly factors
would be present within the above inventory. However,
to date only paraplegin, a conserved subunit of the
ATP-dependent m-AAA protease, links the regulation of
mitoribosome assembly with human mitochondrial
disease based on studies of the paraplegin homologue in
yeast mitochondria and a mouse model (7,8). Therefore, it
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in the regulation of mitochondrial translation, in particu-
lar those involved in the assembly of mitochondrial
ribosomes.
Systematic identiﬁcation of genes that are found in
organisms from several phylogenetic lineages, but remain
largely uncharacterized (‘conserved hypothetical’ proteins)
facilitates prediction of human homologues with import-
ant functions. In this context, we analysed a family of
well-conserved proteins harbouring the YbeB/iojap
domain (also known as DUF143). For two members of
this family, YbeB from Escherichia coli (9) and iojap from
Zea mays, a role in translation regulation has been sug-
gested (10,11). We identiﬁed a human protein that shares
sequence homology with YbeB/iojap—C7orf30. Published
proteomics data (12,13) and our in silico analysis predicted
mitochondrial localization. Therefore, we hypothesized
that C7orf30 is involved in translation in human
mitochondria. Here we show that C7orf30 is indeed a
mitochondrial protein that speciﬁcally associates with
the large 39S subunit of the mitochondrial ribosome
(mt-LSU). We depleted C7orf30 using RNAi and
analysed the mitochondrial ribosomal subunits by
sucrose gradient sedimentation and afﬁnity puriﬁcation
methods. Inactivation of C7orf30 leads to instability of
mt-LSU and a consequent loss of fully assembled ribo-
somes that is accompanied by reduced mitochondrial
translation and respiratory deﬁciency. We propose that
C7orf30 participates in the assembly and/or regulation
of the stability of the large subunit of the mitochondrial
ribosome.
MATERIALS AND METHODS
Plasmids
In order to construct the pcDNA5-C7orf30.FLAG.
STREP2 plasmid used to generate an inducible Flp-In
T-Rex
TM human embryonic kidney 293T (HEK293T)
cell line, the cDNA encoding C7orf30 (cDNA clone
MGC:20424, IMAGE:4646294) was modiﬁed by PCR to
introduce unique KpnI (50) and AgeI (30) sites and the
resulting fragment was cloned into pcDNA5-FST2 con-
structed as described in (14) using the above restriction
sites. The D178A and H185A mutants were generated
using PCR-based mutagenesis and the resulting cDNA
was cloned into pcDNA5-FST2 as above.
Maintenance and transfection of mammalian cell lines
Human HeLa cells that are routinely used by us for im-
munoﬂuorescence localization of mitochondrial proteins
were cultured in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) containing 2mM L-glutamine (Invitrogen)
with 10% FCS (PAA Laboratories). For immunoﬂuores-
cence experiments HeLa cells were transfected with
pcDNA5-C7orf30.FLAG.STREP2 using Lipofectamine
(Invitrogen) according to manufacturer’s instructions.
The Flp-In T-Rex
TM human embryonic kidney 293T
(HEK293T) cell line (Invitrogen), which allows for the
generation of stable doxycycline-inducible expression of
transgenes by FLP recombinase-mediated integration,
was used to express C7orf30.FLAG.STREP2 and the
conserved residue mutants. HEK293T cells were grown
in DMEM containing 2mM L-glutamine (Invitrogen),
10% tetracycline free FCS (Autogen Bioclear) and supple-
mented with 100mg/ml Zeocin (Invitrogen) and 15mg/ml
Blasticidin (Invivogen). Cells were transfected using
Lipofectamine according to the manufacturer’s instruc-
tion. Twenty-four hours after transfection the selective
antibiotics hygromycin (100mg/ml, Invivogen) and
blasticidin (15mg/ml) were added with selective media
replaced every 3–4 days.
Cell fractionation
Cell fractionation was performed as described in (14)
without the sucrose gradient step.
FLAG-tag afﬁnity puriﬁcation
Mitochondria were isolated from HEK293T cells
overexpressing ICT1.FLAG, MRPS27.FLAG or PDE12.
FLAG essentially as described in (15). Pelleted mito-
chondria were resuspended in lysis buffer and immunopre-
cipitation (IP) was performed with a FLAG M2 afﬁnity
gel (Sigma) following manufacturer’s recommendations.
Elution was effected with the FLAG peptide.
Immunodetection of proteins
The localization of proteins by immunoﬂuorescence in
ﬁxed HeLa cells was performed as described previously
(16). The following antibodies were used: mouse anti-
Flag IgG (Sigma, 1:200), FITC-conjugated anti-mouse
IgG (Sigma, 1:200). Immunoﬂuorescence images were
captured using a Zeiss LSM 510 META confocal
microscope.
For immunoblot analysis equal amounts of protein cor-
responding to total cell lysates or protein fractions were
subjected to SDS–PAGE, semi-dry transferred to nitrocel-
lulose membranes, blocked in 5% non-fat milk (Marvel)
in PBS for 1h and incubated with speciﬁc primary
antibodies in 5% non-fat milk in PBS for 1h or overnight.
The blots were further incubated with HRP-conjugated
secondary antibodies in 5% non-fat milk in PBS for 1h
and visualized using ECL+(Amersham).
The primary antibodies used were: rabbit anti-C7orf30
(Sigma, 1:1000), mouse anti-FLAG IgG (Sigma, 1:5000),
mouse anti-b-actin IgG (Sigma, 1:7000), mouse anti-CO2
IgG (Abcam, 1:5000), rabbit anti-SSB1 IgG (kindly
donated by Prof. D. Kang, 1:4000), mouse anti-GAPDH
IgG (Abcam, 1:10000), mouse anti-complex I subunit
NDUFB8 (MitoSciences, 1:2000), mouse anti-complex II
subunit 30kDa (MitoSciences, 1:2000), mouse anti-
complex III subunit core 2 (MitoSciences, 1:2000),
mouse anti-DAP3/MRPS29 IgG (Abcam, 1:1000) and
goat anti-MRPL3 (Abcam, 1:1000), mouse anti-
MRPL12 (Abcam, 1:1000), rabbit anti-MRPS18B
[Proteintech group (PTG), 1:1000].
Secondary antibodies were: anti-rabbit IgG-HRP
(Promega, 1:2000), anti-mouse IgG-HRP (Promega,
1:2000) and anti-goat IgG-HRP (Sigma, 1:1000)
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Stealth
TM siRNAs were obtained from Invitrogen and
delivered to cells using Lipofectamine RNAiMAX.
Stealth
TM RNAi duplexes were generated using the fol-
lowing sequences: C7orf30 siRNA1: UCGAUAUGAUG
GUUUCACUUCUGAG and C7orf30 siRNA2: CGACA
CUUACAUGCCAUGGCCUUCU.
Measurement of mitochondrial respiration
HeLa cells transfected with siRNA against C7orf30 were
seeded at 3 10
4 cells/well in 200ml growth medium in XF
24-well cell culture microplates (Seahorse Bioscience) and
incubated at 37 Ci n5 %C O 2 for 36–40h. One hour
before the assay growth medium was removed and
replaced with assay medium (low buffered DMEM,
10mM L-glutamine, 1mM sodium pyruvate, 2mM
glucose), with one wash of assay medium, and left to
stabilize in a 37 C non-CO2 incubator. Analysis was
performed in quadruplicate using a XF24 Extracellular
Flux Analyzer (Seahorse Bioscience). The wells were
sequentially injected with 20mM 2-deoxyglucose (2-DG)
to inhibit glycolysis, 100nM oligomycin to inhibit
ATP-synthase, 500–1000nM carbonylcyanide-4-
triﬂuorometho-xyphenylhydrazone (FCCP) to uncouple
the respiratory chain, and 200nM rotenone to inhibit
complex I. Oxygen consumption rate (OCR) was
measured for each well every 5min. before and after
each injection. Test compounds: 2-DG, oligomycin,
FCCP and rotenone were all obtained from Sigma.
35S-methionine metabolic labelling of mitochondrial
proteins
HeLa cells transfected with siRNA against C7orf30 or
stably transfected HEK293T cells expressing C7orf30.
FLAG.STREP2 or mutants thereof were induced with
doxycycline (50ng/ml) for 3 days prior to
35S labelling.
Growth medium was replaced with methionine/cysteine-
free DMEM (Sigma) supplemented with 2mM L-glutam-
ine, 48mg/ml cysteine and 50mg/ml uridine. The cells
were incubated for 2 10min in this medium, then
transferred to methionine/cysteine-free DMEM medium
containing 10% (v/v) dialysed FCS and emetine
dihydrochloride (100mg/ml). Cells were incubated for
10min before addition of 120mCi/ml of [
35S]-methionine.
Labelling was performed for 15min and the cells were
washed twice with standard growth medium. Protein
samples (30mg) were separated on 4–12% SDS–PAGE
gels, with products visualized and quantiﬁed using a
PhosphorImager system in ImageQuant software
(Molecular Dynamics, GE Healthcare).
Analysis of mitochondrial ribosome proﬁle on density
gradients
Total cell lysates (0.7mg) were loaded on a linear sucrose
gradient [2 ml 10–30% (v/v)] in 50mM Tris–HCl (pH 7.2),
10mM Mg(OAc)2,8 0 m MN H 4Cl, 0.1M KCl, 1mM
PMSF and centrifuged for 2h 15min at 100000gmax at
4 C (39000rpm, Beckman Coulter TLS-55 rotor).
Twenty fractions (100ml) were collected and 10-ml
aliquots were analysed directly by western blotting.
RNA isolation and northern blotting
Total RNA from HeLa cells was isolated using Trizol
(Invitrogen) according to the manufacturer’s instructions.
For northern blots, RNA was resolved on 1% agarose gels
containing 0.7M formaldehyde in 1 MOPS buffer, trans-
ferred to a nylon membrane in 2  SSC and hybridized
with radioactively labelled PCR fragments corresponding
to appropriate regions of mtDNA or 28S rDNA.
RESULTS
Identiﬁcation of C7orf30 and in silico analysis of
proteins containing the DUF143 domain
Analysis of the primary structure of C7orf30 by pairwise
alignment revealed an evolutionarily well-conserved
domain of unknown function named DUF143.
The DUF143 domain of C7orf30 (residues 93–194)
shares 33% sequence identity with YbeB of E. coli
(residues 6–105), which has been reported to associate
with the large subunit (50S) of the bacterial ribosome
(9,17) and 29% sequence identity with iojap of Zea
mays (residues 116–213), a protein which is involved in
the regulation of chloroplast ribosome stability (10,11).
Additionally, 24% of residues within the DUF143
domain of C7orf30 are identical to the N-terminal
domain of Saccharomyces cerevisiae ATP25 protein
(residues 104–246), which is required for the expression
and assembly of the Atp9p subunit of the mitochondrial
ATPase (18) (Figure 1A and B). Bacterial YbeB and plant
iojap share a similar domain architecture to C7orf30, with
the DUF143 domain located at the C-terminus of these
proteins. In ATP25, however, the DUF143 domain is
located within the N-terminal portion of the protein and
the C-terminus shares weak sequence homology with the
metallo-beta-lactamase superfamily (Figure 1B). Three
dimensional structures of two proteins containing the
DUF143 domain have been solved: uncharacterized
protein CV0518 from Chromobacterium violaceum (PDB:
2id1) and uncharacterized protein BH1328 from Bacillus
halodurans (PDB: 2o5a). On the basis of structural
features, DUF143 has been assigned to the superfamily
of nucleotidyltransferases (NTases) (19), enzymes that
transfer nucleoside monophosphate (NMP) from nu-
cleoside triphosphate (NTP) to an acceptor hydroxyl
group belonging to a protein, nucleic acid or small
molecule. NTases are characterized by the presence of a
common minimal core of a-b-a-b-a-b-a topology (19)
(Figure 1). NTases contain the following common
sequence motifs which include conserved active site
residues involved in the coordination of divalent ions:
(i) [DE]h[DE]h (h indicates a hydrophobic amino acid)
located on the second core b-strand and (ii) h[DE]h
placed on the third b-strand (Figure 1C and D, see
hmtCCAse). Our 3D homology modelling of C7orf30
based on the crystal structure of 2id1 indicated that
none of the three active site aspartate/glutamate residues
are conserved in C7orf30 suggesting that the protein is not
an active NTase.
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Several computer programmes that analyse the
N-terminal region of proteins for the presence of a poten-
tial mitochondrial targeting sequence (MTS) indicated a
high probability of a MTS in C7orf30 (MitoProt II 98%,
MultiLoc 95%, TargetP 84%, Predotar 67%, PSORT
(mitochondrial matrix) 50%, PSORT II 45%).
Moreover, C7orf30 was reported to be present in the
mitochondrial proteome of a motor neuron-like cell
line, NSC34 (12). In order to study the cellular
localization of C7orf30 we transiently expressed the
corresponding cDNA with a FLAG tag in HeLa cells.
Immunoﬂuorescence analysis revealed that the recombin-
ant protein co-localizes with mitochondria (Figure 2A).
Cell fractionation experiments conﬁrmed the mitochon-
drial localization of the protein, as endogenous
C7orf30 co-fractionated with the well-characterized mito-
chondrial matrix protein, mtSSB1, and was resistant to
proteinase K treatment. In similar conditions the outer
membrane protein TOM22 was truncated by proteinase
K (Figure 2B). These results suggest that C7orf30 is
localized within the mitochondria of human cells.
C7orf30 associates with the large subunit of the
mitochondrial ribosome
Since C7orf30 shares sequence homology with the YbeB
protein that associates with the large subunit of the bac-
terial ribosome, we set out to determinate whether the
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Figure 1. Properties of the NTase-like fold of C7orf30. (A) Multiple protein sequence alignment of the DUF143 domain. Protein sequence of the
DUF143 domain (PFAM: PF02410) of E. coli YbeB (Genbank Accession No. NP_752658), Z. mays iojap (Genbank Accession No. NP_001105495),
S. cerevisiae Atp25p (Genbank Accession No. NP_013816) and human C7orf30 (Genbank Accession No. NP_612455) were extracted from the
PFAM database (42) and aligned using CustalW2. The boundaries of the sequence segment used in the alignment are indicated. Colons and dots
denote chemical similarity between the sequences, whereas asterisks indicate identical residues. The secondary structure based on the resolved
structure of the bacterial DUF143 protein CV0518 (pdb: 2id1) is indicated above the alignment [helix (cylinders), strand (arrow)]. Three b-sheets
(numbered 1–3) and four a-helices of NTases a/b-fold are presented in red and yellow, respectively. (B) Domain architecture of proteins comprising
the DUF143 domain. Functional domains of proteins containing DUF143 are schematically represented. The position of the DUF143 domain is
indicated and represented in each protein by an orange box containing the percentage of identical residues between this domain and that of C7orf30.
The green box represents a partial metallo-beta-lactamase domain (PFAM: PF00753) found in Atp25p using PSI-BLAST searches. (C) A comparison
of C7orf30 NTase-like fold with that of a known NTase. Protein sequence alignment of the three core b-strands of the NTase fold (yellow) (43) of
the human mitochondrial CCA tRNA nucleotidyltransferase 1 (hmtCCAse) (PDB: 2ou5), bacterial YbeB-type protein from C. violaceum (CV0518)
(PDB: 2id1) and predicted core b-strands of the homology model of C7orf30 constructed with the reference to the crystal structure of CV0518. The
two conserved aspartates (D) and a glutamate (E) involved in coordination of divalent ions by hmtCCAse are indicated in blue and cyan, respect-
ively. Corresponding residues in the CV0518 structure and the C7orf30 model are also coloured. (D–F) Ribbon diagrams indicating the key
secondary structure elements of the NTase fold. The structures of hmtCCase (D), CV0518 (E) and the homology model of C7orf30 (F) are presented.
The three-stranded, mixed b-sheets (yellow) and four a-helices (red) of the common core of the minimal fold are presented. The conserved aspartate/
glutamate residues and the corresponding residues in CV0518 and the C7orf30 model are shown as sticks and colour coded as presented in C.
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investigate this, we carried out sucrose gradient sedimen-
tation of human HeLa cell extracts followed by detection
of C7orf30 and the components mt-SSU (28S) and
mt-LSU (39S) by western blotting of gradient fractions.
We used MRPS18B or DAP3/MRPS29 as markers
for mt-SSU and MRPL3 or MRPL12 as markers
for mt-LSU. Analyses of the sedimentation of mito-
ribosomal subunits revealed that C7orf30 is located in
fractions positive for the mt-LSU markers (Figure 3A,
fractions 9–12) and low molecular weight fractions
(Figure 3A, fractions 1–6). These results indicate that a
part of the mitochondrial pool of C7orf30 associates with
mt-LSU. A proportion of C7orf30 that is found at the top
of the gradient likely represents free protein or protein in a
low molecular weight complex, similarly to the MRPL12
protein (Figure 3A, fractions 1–6). A very similar sedimen-
tation pattern has been obtained for YbeB, the bacterial
homologue of C7orf30 (9).
In order to gain further insights into the interaction of
C7orf30 with the mitoribosome, we performed pull-down
experiments in Flp-In T-Rex
TM Human embryonic
kidney (HEK293T) cell lines inducibly expressing
either FLAG-tagged MRPS27, a component of mt-SSU,
or FLAG-tagged ICT1, a component of mt-LSU (15).
It has been reported previously that MRPS27.FLAG
and ICT1.FLAG are able to pull-down components of
mt-SSU or mt-LSU, respectively, with each of these
proteins also capable of pulling down the entire
monosome (15). We have performed IP with anti-FLAG
antibodies after inducing MRPS27.FLAG or ICT1.FLAG
for 3 days with 50ng/ml doxycycline and analysed the
eluates by western blotting. The C7orf30 protein
co-puriﬁed with ICT1.FLAG (Figure 3B, lane 2) consist-
ent with the interaction of C7orf30 with mt-LSU. The lack
of other highly abundant mitochondrial proteins, such as
subunit 2 of complex IV (CO2), in the elution fraction
implies speciﬁc interaction (Figure 3B). In contrast,
C7orf30 was absent from the elution fraction of the
MRPS27.FLAG IP suggesting that the C7orf30 protein
does not interact with mt-SSU (Figure 3B, lane 4).
Proteins of mt-LSU (MRPL3 and MRPL12) were
present in the elution fraction of the MRPS27.FLAG
IP, consistent with co-puriﬁcation of the intact mitochon-
drial monosome (Figure 3B, lane 4). However, the lack of
C7orf30 in this fraction suggests that the protein does
not bind to the fully assembled mitoribosome. Finally,
the speciﬁcity of C7orf30 association with mt-LSU was
further conﬁrmed in an IP experiment with a FLAG-
tagged version of the PDE12 protein (PDE12.FLAG)
that according our previous studies is a mitochondrial
RNase not associated with the mitoribosome (20).
There was no C7orf30 nor any mitoribosomal pro-
teins readily detected in the IP experiment with
PDE12.FLAG (Figure 3B, lane 5). Taken together, the
results of sedimentation of C7orf30 on sucrose gradients
and the IP experiments indicate that the C7orf30 protein
associates exclusively with the large subunit of the mito-
chondrial ribosome.
C7orf30 is necessary for OXPHOS function
In order to assess the role of C7orf30 in OXPHOS, we
silenced the expression of the gene by siRNA. We
identiﬁed two siRNAs that depleted the protein in HeLa
cells as veriﬁed by western analysis (Figure 4A), however,
‘siRNA 1’ was more effective as compared to ‘siRNA 2’,
which was particularly apparent after 3 days of siRNA
treatment (Supplementary Figure S1). Upon inactivation
of C7orf30 a reduction in the steady-state levels of the
respiratory chain subunits was observed, which correlated
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Figure 2. Mitochondrial localization of C7orf30. (A) The intra-cellular
localization of C7orf30 by immunoﬂuorescence. The cDNA encoding
the STREP2- and FLAG-tagged variant of C7orf30
(C7orf30.FLAG.STREP2) was transiently transfected into HeLa cells.
Cell nuclei were stained with DAPI (blue, 1). C7orf30.FLAG.STREP
was detected by anti-Flag antibody and visualised by secondary
antibodies conjugated with FITC (green, 2). Mitochondria were
stained with MitoTracker Red CMXRos (red, 3). Co-localization of
the mitochondria-speciﬁc red signal and C7orf30-speciﬁc green signal
appears yellow on digitally merged images (4). (B) Location of C7orf30
in sub-cellular fractions. The HeLa cells were fractionated into debris
(D, lane 2), cytosol (C, lane 3) and mitochondria (lanes 4–6). The
mitochondrial fraction was treated with 25mg/ml proteinase K in the
absence (lane 5) or presence of 1% Triton X-100 (lane 6). ‘T’ indicates
the total cell lysate. The fractions were analysed by western blotting
using antibodies to C7orf30. The location of C7orf30 was compared
with that of the following marker proteins: mtSSB1 (mitochondrial
matrix side), TOM22 (mitochondrial outer membrane) and GAPDH
(cytosol). ‘ﬂ’ means TOM22 of full length, ‘tr’ means truncated
TOM22.
Nucleic Acids Research,2012, Vol.40, No. 9 4101well with the effectiveness of the speciﬁc siRNA
(Figure 4A). Although almost complete knockdown of
C7orf30 was observed after 6 days for the two siRNAs
(Figure 4A and Supplementary Figure S1), it is expected
that differences in the reduction of steady-state levels of
the OXPHOS components between the two siRNAs result
from an unequal rate of gene inactivation.
Inhibition of C7orf30 expression by ‘siRNA 1’ over 6
days reduced the abundance of complexes I and IV
subunits by 70 and 65%, respectively (Figure 4B). The
steady-state levels of a component of complex III was
also down-regulated, though to a lesser extent—by 30%
after 6 days of siRNA treatment (Figure 4B). There was
no marked reduction in the steady-state levels of complex
II, containing only nuclearly encoded subunits, suggesting
that the C7orf30 depletion interferes only with mitochon-
drial gene expression. The observed decrease in respira-
tory chain components was accompanied by a reduced
cellular OCR of <50% (Figure 4C). Quantiﬁcation of
the steady-state levels of mitochondrial mRNAs and
rRNAs in cells subjected to C7orf30 RNAi did not
reveal any marked reductions (Figure 4D). These results
indicate that C7orf30 plays an important role in mito-
chondrial energy production. Given its association with
the mitoribosome, and lack of observed reduction in the
steady-state levels of mitochondrial transcripts upon gene
inactivation we hypothesized that this role is fulﬁlled via
contributions to mitochondrial translation.
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Figure 3. Interaction of C7orf30 with the mitochondrial ribosome. (A) Endogenous C7orf30 co-sediments with the large subunit of the mitochon-
drial ribosome. Total lysate of HeLa cells was separated through a 10–30% (v:v) isokinetic sucrose gradient and fractionated. The fractions were
analysed by western blotting with antibodies speciﬁc for C7orf30, components of mt-LSU (MRPL3 and MRPL12) and components of mt-SSU
(DAP3/MRPS29 and MRPS18B). Western blot signal was quantiﬁed using ImageQuant software and presented in the graph above. (B) IP of the
endogenous C7orf30 with the mitochondrial ribosome. Cells expressing MRPS27.FLAG (a component of mt-SSU), ICT1.FLAG (a component of
mt-LSU) or PDE12.FLAG (mitochondrial RNase that does not associate with the mitoribosome) were lysed and IP was performed using anti-FLAG
antibodies. The lysates (‘Input’) and eluates were analysed by western blot with the antibodies as indicated in A. CO2—antibody against subunit 2 of
mitochondrial complex IV.
4102 Nucleic Acids Research, 2012,Vol.40, No. 9C7orf30 gene silencing inhibits mitochondrial translation,
alters the proﬁle of mt-LSU and results is reduction of
monosome formation
In order to establish whether OXPHOS defects observed
upon inactivation of C7orf30 (Figure 4) were a result of
impaired mitochondrial protein synthesis, we inhibited
cytosolic translation and labelled de novo synthesized
mitochondrially encoded subunits of the electron trans-
port chain with
35S-Met. The incorporation of radioactive
35S-Met into mitochondrial proteins was analysed 6 days
after the HeLa cells were transfected with C7orf30 siRNA.
Translation of all mitochondrially encoded respiratory
chain subunits was compromised upon C7orf30 gene
silencing, with incorporation of
35S-Met reduced by
<60% (for the more potent C7orf30 siRNA oligo 1) as
compared to controls transfected with an unrelated
siRNA (Figure 5A). In order to investigate whether
inactivation of C7orf30 has an effect on the integrity
of the mitochondrial ribosome, we carried out gradi-
ent sedimentation analyses of lysates from HeLa cells
transfected with C7orf30 siRNA for 6 days and control
cells transfected with an unrelated siRNA (Figure 5B
and Supplementary Figure S2). Analysis of the sedimen-
tation of mitoribosomal subunits upon silencing of
C7orf30 revealed anomalous sedimentation of mt-LSU.
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and MRPL12) relocated to less dense fractions as
compared to control cells (Figure 5C and D, fraction 8).
The proﬁle of the mt-SSU marker MRPS18B was largely
unchanged after C7orf30 depletion (Figure 5E). Of note,
the steady-state levels of the component of mt-SSU and
mt-LSU have not been altered upon silencing of C7orf30
(Figure 4A). Next we examined whether the alterations in
mt-LSU sucrose gradient proﬁle observed in C7orf30-
depleted cells result in a concomitant reduction in the
level of the intact monosome. We pulled-down mt-LSU
and the entire monosome using a FLAG-tagged compo-
nent of the large subunit, ICT1.FLAG, from control cells
and cells treated with siRNA to C7orf30 for 6 days, then
analysed the eluates by western blotting (Figure 5F and
Supplementary Figure S3). The components of mt-LSU
were equally well pulled-down for control and C7orf30-
depleted cells (Figure 5F, lane 2 and Figure 5G). However,
there was a 60% reduction in the levels of the
mt-SSU proteins (DAP3/MRPS29 and MRPS18B) in
the C7orf30-depleted cells (Figure 5F, lane 4 and
Figure 5G), consistent with a decrease in monosome
formation, presumably due to alterations in mt-LSU in-
tegrity. These results, together with the observation that
the steady-state levels of mitochondrial rRNAs were not
changed (Figure 4D), suggest that the inhibition of mito-
chondrial translation upon inactivation of C7orf30 could
be attributed mainly to instability and/or impaired
assembly of the large mitoribosomal subunit, conse-
quently interfering with formation of the mitochondrial
monosome.
Overexpression of C7orf30 mutant alters the
proﬁle of mt-LSU
In order to further investigate how C7orf30 contributes to
regulation of the biogenesis of mt-LSU, we overexpressed
mutants of the protein in human mitochondria. A FLAG-
and STREP2-tagged version of C7orf30 (C7orf30.FLAG.
STREP2) was stably transfected into HEK293T cells.
Similarly to the endogenous C7orf30, the recombinant
protein was associated with mt-LSU as veriﬁed by
sucrose gradient sedimentation of HEK293T cell ex-
tracts after induction of the transgene for 3 days with
50ng/ml of doxycycline (Figure 6). Overexpression of
A
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adverse effect on the mitoribosome proﬁle (Figure 6).
However, we reasoned that overexpressed mutants
of C7orf30 might exhibit dominant-negative effects
through, for example, outcompeting the endogenous
protein for mitoribosome binding. We selected two
residues conserved between C7orf30 orthologues, bacter-
ial DUF143-containing proteins and iojap: D178 and
H185 (Figure 6A). These residues were replaced with
alanines via site-directed mutagenesis and cDNAs
encoding the D178A or H185A mutants with the
FLAG.STREP2 tag were stably integrated into the gen-
ome of HEK293T cells. Overexpression of the H185A
mutant, but not D178A (Supplementary Figure S4) for 3
days with 50ng/ml doxycycline resulted in a signiﬁcant
alteration to the proﬁle of mt-LSU as assessed by
sucrose gradient sedimentation and western blotting with
speciﬁc antibodies. A signiﬁcant proportion of the
mt-LSU marker (MRPL3) migrated in less dense frac-
tions typical for low molecular weight complexes as
compared with control cells expressing wild-type
C7orf30 (Figure 6B, fractions 1–4). The sedimentation
of the H185A mutant (Figure 6B, fractions 7 and 8) was
different from wild-type C7orf30, suggesting an inter-
action with sub-ribosomal complex(es) rather than the
fully assembled mt-LSU. The proﬁle of the mt-SSU
marker, MRPS18B, was essentially unchanged after
overexpression of the H185A mutant. The changes in
the mitoribosomal proﬁle in cells overexpressing the
H185A mutant were accompanied by reduced mitochon-
drial protein synthesis as measured by incorporation of
radioactive
35S-Met into mtDNA-encoded proteins
(Figure 6C). These results provide further evidence that
C7orf30 is important for regulation of the stability and/or
assembly of the large mitoribosomal subunit and suggest
that b-sheet 3 of the conserved NTase-type fold is import-
ant for this process.
DISCUSSION
In all biological systems translation of the genetic infor-
mation into proteins is carried out by the ribosome.
Complex regulatory pathways have evolved to modulate
ribosomal function in response to various stimuli. Many
protein factors regulate ribosome synthesis including
those involved in rRNA processing and modiﬁcation,
trans-acting assembly factors, chaperones and a variety
of stress response proteins. We propose that the novel
human protein C7orf30 participates in the biogenesis of
the mitochondrial ribosome, in particular the biosynthesis
of the large 39S mitoribosomal subunit.
C7orf30 does not regulate mitochondrial
translation at RNA level
In yeast mitochondria a group of regulatory proteins
exists to optimize the translation of individual mRNAs.
The regulatory role of these proteins can be exerted
through regulation of the stability of speciﬁc transcripts
or by binding to the 50-UTRs of mRNAs and assisting in
translation initiation (21). Such translation regulatory
proteins have also been reported in mammalian
mitochondria implying that, despite signiﬁcant differences
in mitochondrial mRNA architecture (for example: the
length of UTRs or RNA polyadenylation), the require-
ment for precise regulation of the translation of individual
transcripts is evolutionarily conserved. The TACO1
protein (CCDC44) has been identiﬁed as a speciﬁc trans-
lational activator of CO1—lack of TACO1 results in sig-
niﬁcantly reduced synthesis of the CO1 protein despite
normal steady-state levels of the CO1 mRNA (5).
Several human proteins of the pentatricopeptide (PPR)
family have been proposed to play a regulatory role in
mitochondrial translation. The PPR family of proteins is
characterized by the presence of a tandemly repeated,
35-amino acid motif. Most studies of plant PPR proteins
thus far have indicated various roles in RNA turnover,
processing or translational regulation in mitochondria or
chloroplasts (22). Mutations in human leucine-rich
PPR-motif containing protein, LRPPRC (or LRP130)
cause the French Canadian variant of Leigh syndrome
(LSFC) (23), with proposed functions in positive transla-
tional control of mitochondrially encoded subunits of
COX (24,25). Other human mitochondrial PPR proteins
involved in the regulation of speciﬁc events in RNA me-
tabolism or translational control include: (i) PTCD1, a
negative regulator of translation acting by modulating
the abundance of the leucine tRNAs (26), PTCD2, a regu-
lator of cytochrome B mRNA maturation (27) and
PTCD3, which modulates mitochondrial protein synthesis
via binding to 12S rRNA (28).
Given the structural homology of C7orf30 to NTases,
which are mostly nucleic acid modifying enzymes, one of
our initial hypotheses for the function of the protein in
mitochondria considered its involvement in translation
regulation at the RNA level. This position was initially
supported by the observation that C7orf30 shares
sequence homology with the yeast mitochondrial ATP25
protein (Figure 1), required for the processing and stabil-
ity of ATP9 mRNA (18). Zeng et al. showed that muta-
tions in ATP25 result in decreased levels of the ATP9
mRNA and its translation product thereby precluding
assembly of the functional F0 subunit of ATP synthase.
However, the same study has shown that only the
C-terminal fragment of Atp25p is sufﬁcient to stabilize
the ATP9 mRNA and restore synthesis of Atp9p (18).
Our analysis revealed that the C-terminal section of
Atp25p shares sequence homology with the
metallo-beta-lactamase domain (Figure 1B), present in
many RNA processing enzymes, such as mitochondrial
RNAse Z (29). As an equivalent of the Atp25p
C-terminal domain is absent from C7orf30, it is likely
that the human protein is not involved in regulating
RNA processing and/or stability. Consistent with this
conclusion is the absence of key catalytic residues of the
NTase fold (Figure 1) suggesting that C7orf30 is not an
active nucleic acid modifying enzyme. Also, our results of
downregulation and overexpression (Joanna Rorbach and
Payam Gammage, unpublished work) of C7orf30 showed
no appreciable changes in the steady-state levels of any of
the mitochondrial RNAs analysed (Figure 4D).
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A complex, multi-step pathway precedes ribosome produc-
tion in all organisms studied thus far. In the yeast cyto-
plasm, approximately 200 proteins and 70 small nucleolar
RNAs have been reported to participate in ribosome bio-
synthesis and at least half of these proteins are believed to
function directly in the assembly and/or transport of
pre-ribosomal complexes from the nucleolus to the cyto-
plasm (30). Trans-acting assembly factors are also involved
in biosynthesis of the bacterial ribosome. However, owing
to the lack of compartmentalization of ribosome synthesis
steps fewer proteins are involved in this process. In
contrast to the relatively well-studied ribosomal assembly
pathway in bacteria and eukaryotic cytoplasm, assembly of
the mammalian mitoribosome remains to be described.
Only two proteins playing a role in the biogenesis of
mammalian mt-SSU have been identiﬁed. A homologue
of bacterial Era protein, ERAL1, a member of the
conserved family of GTP-binding proteins with RNA-
binding activity, has been demonstrated to play a role in
the formation mt-SSU (31,32). It has been suggested that
ERAL1 functions as a mitochondrial RNA chaperone to
protect 12S rRNA on mt-SSU during assembly (31).
TFB1M (transcription factor B1, mitochondrial) is re-
sponsible for adenine dimethylation of 12S rRNA and
its knock-out in mice causes impaired assembly of the
mitochondrial ribosome (33). Trans-acting, non-ribosomal
factors such as protein chaperones involved in the
assembly of mt-SSU are yet to be found.
The complement of proteins comprising mt-LSU has
been described by Spremulli and co-workers a decade
ago (34), however, there is very limited published data
on protein factors involved in assembly of this subunit.
Multiple GTPases participate in the assembly of LSU in
bacteria and eukaryotes (30). The yeast Mtg1p protein, a
homologue of bacterial YlqF GTPase (also known as
RbgA) (35), has been suggested to function in the
assembly of the ribosome in yeast mitochondria without
a role in transcription or processing of mt-rRNAs (36).
The evidence that a human orthologue of Mtg1p partici-
pates in an analogous process within mitochondria is cir-
cumstantial, though. Human Mtg1 is capable of partial
rescue of respiratory deﬁciency in a yeast mtg1 mutant
and it has been localized to mitochondria in human cells
(36). Knock-out of NOA1 (c4orf14, mAtNOS1)—a
member of the circularly permuted GTPase (cpGTPase)
family—in mouse cells led to impaired protein synthesis
without loss of mtDNA and/or transcription. It has been
suggested NOA1 plays a role in the assembly of mt-LSU
(37). hMTERF4, a member of the family of mitochondrial
proteins involved in transcription regulation (38), forms a
complex with a putative RNA m5C methyltransferase
NSUN4. The hMTERF4-NSUN4 complex co-migrates
with mt-LSU and participates in the assembly of the
monosome (39). Lastly, another non-ribosomal protein
involved mitoribosomal biogenesis is mitochondrial
AAA (m-AAA) protease that processes MRPL32 at the
late stages of the assembly (8).
Our data indicate that C7orf30 is important for the
assembly and/or stability of the mitochondrial ribosome,
in particular the large 39S subunit. Consistent with the
role of the DUF143 domain in ribosome assembly and/
or stability is the phenotype of homozygous mutants of
iojap in Zea mays; the plant homologue of C7orf30
(Figure 1A and B). Maize iojap is localized to plastids,
and mutations in the coding gene result in depletion of
chloroplast ribosomes and defects in translation. It has
been previously suggested that the iojap phenotype
results from impaired plastid ribosome assembly (10,11).
Our results clearly show that RNAi-mediated depletion of
C7orf30 or overexpression of a mutant of the conserved
H185 residue compromised the integrity of mt-LSU. Our
data also suggest that C7orf30 participates in late stages of
assembly as relatively high molecular weight assembles are
still present after C7orf30 depletion. Consistent with this
are the results of afﬁnity puriﬁcation of the large subunit
using ICT1.FLAG. C7orf30 was clearly enriched with
ICT1.FLAG, and recently published data conﬁrmed that
ICT1 is an important component of the complete mono-
some, not assembly intermediates. Also, the bacterial
homologue of C7orf30, YbeB, puriﬁes with the large ribo-
somal subunit (9), but not the 50S* particle (17), which
constitutes a penultimate pre-ribosomal complex in the
bacterial ribosome assembly pathway (40). Furthermore,
in bacteria YbeB exists in an operon together with ORFs
encoding proteins involved in late large subunit biogenesis
(41). We could speculate that the DUF143 domain
evolved to promote interactions between subunits of
large complexes such as the ribosome or ATP synthase.
The N-terminal fragment of Atp25p, the yeast homolog of
C7orf30, contains the DUF143 domain. This N-terminal
fragment plays a role in the oligomerization of Atp9p, a
subunit of the F0 portion of the yeast mitochondrial ATP
synthase, into a correct size ring structure (18). An analo-
gous role could be played by C7orf30 in assembly of the
mitoribosomal large subunit.
In conclusion, C7orf30 is a novel human gene indispens-
able for mitochondrial translation, most probably via its
contribution to the biogenesis of mt-LSU. The function of
C7orf30 in mt-LSU is also supported by the study of
Wanschers et al. (41). In this context C7orf30 could be
prioritized for analysis as a candidate disease gene in
patients with combined OXPHOS deﬁciencies. Further
studies of this protein, for example by cross-link IP
approach, should provide new insights into the largely
unknown area of mitochondrial ribosome biogenesis
pathway and could be helpful in identifying other
protein factors involved in this process.
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